Dapagliflozin

Category: pharmacological

Aliases: Farxiga, Forxiga, BMS-512148

Pharmacological Mechanism

Selective SGLT2 inhibitor — first-in-class (approved EU 2012, US 2014). Mechanism + glucosuric output comparable to empagliflozin; slightly lower SGLT2:SGLT1 selectivity (~1400-fold). DAPA-HF established HFrEF benefit independent of diabetes status; DAPA-CKD established CKD progression reduction.

Half-Life (t½)

PO: 12.9h

Dosing Guidelines

• PO: Typical 6.67mg (Range: 5 - 10 mg)

Target Organ Systems

• endocrine
• digestive
• renal

Interactions

• Empagliflozin
• Metformin